No Data
No Data
Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?
Boteng shares: 2024 semi-annual report
Boteng Shares: 2024 Semi-Annual Report Summary
Porton Pharma Solutions (300363.SZ) released its semi-annual performance, with a net loss of 0.17 billion yuan, a year-on-year reversal from profit to loss.
Porton Pharma Solutions (300363.SZ) disclosed the semi-annual report for the first half of 2024. In the reporting period, the company achieved revenue of 1 million yuan...
Porton Pharma Solutions (300363.SZ): Net loss of 0.17 billion yuan in the first half of the year, turning from profit to loss year-on-year.
Porton Pharma Solutions (300363.SZ) announced its 2024 interim report on August 27th. During the reporting period, the revenue was 1.352 billion yuan, a decrease of 42.19% year-on-year; the net income attributable to shareholders of the listed company was -0.17 billion yuan, turning from profit to loss year-on-year; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -0.174 billion yuan; and the basic earnings per share was -0.31 yuan.
What Porton Pharma Solutions Ltd.'s (SZSE:300363) P/S Is Not Telling You
No Data